title: Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study.
abstract: OBJECTIVE
  Previous prospective studies of the surgical treatment of locally advanced prostate cancer have enrolled patients selected on the basis of a limited T3 disease extension. The aim of the present study was to assess the feasibility and the oncologic outcome of radical prostatectomy administered to a consecutive unselected series of advanced, non-bone metastatic prostate cancers.
  
  
  METHODS
  Between March 1998 and February 2003 radical prostatectomy was offered at our institution to any patient diagnosed with prostate cancer with no sign of extranodal metastatic disease. Data on morbidity and survival for 51 clinically advanced cases (any T>/=3, N0-N1, or any N1 or M1a disease according to the TNM 2002 classification system) operated on by a single expert surgeon were compared with a series of 152 radical prostatectomies performed during the same period by the same operator for clinically organ-confined disease. Adjuvant treatment was administered according to current guidelines.
  
  
  RESULTS
  The two groups did not differ significantly in surgical morbidity except for blood transfusion, operative time, and lymphoceles, which showed a higher rate in patients with advanced disease. The Kaplan-Meier estimate of overall survival and prostate cancer-specific survival at 7 yr were 76.69% and 90.2% in the advanced disease group and 88.4% and 99.3% in the organ-confined disease group, respectively.
  
  
  CONCLUSIONS
  Even in the scenario of extensive surgical indications up to M1a disease, radical prostatectomy proved to be technically feasible and to have an acceptable morbidity rate compared with organ-confined disease. Our initial survival data strengthen the role for surgery as an essential part in the multimodal approach to treating advanced prostate cancer.
authors.affiliation: Clinica Urologica I, Università degli Studi di Torino, Torino, Italy. paolo.gontero@unito.it
authors.forename: Paolo
authors.initials: P
authors.lastname: Gontero
authors.forename: Giansilvio
authors.initials: G
authors.lastname: Marchioro
authors.forename: Roberta
authors.initials: R
authors.lastname: Pisani
authors.forename: Stefano
authors.initials: S
authors.lastname: Zaramella
authors.forename: Filippo
authors.initials: F
authors.lastname: Sogni
authors.forename: Ervin
authors.initials: E
authors.lastname: Kocjancic
authors.forename: Nicola
authors.initials: N
authors.lastname: Mondaini
authors.forename: Daniele
authors.initials: D
authors.lastname: Bonvini
authors.forename: Alessandro
authors.initials: A
authors.lastname: Tizzani
authors.forename: Bruno
authors.initials: B
authors.lastname: Frea
mesh_terms: D000368:Aged; D005240:Feasibility Studies; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology / Q000601:surgery*